Olezarsen Lowers Triglycerides 57%–65% in Patients With Severe Hypertriglyceridemia and Diabetes
Key Highlights
- Among 1,063 participants in CORE-TIMI 72a and CORE2-TIMI 72b, 673 had diabetes.
- Placebo-adjusted triglyceride reductions at 6 months were 57.4% with olezarsen 50 mg and 64.8% with 80 mg among participants with diabetes.
- Participants with diabetes had a higher acute pancreatitis rate than those without diabetes.
- Pooled olezarsen treatment reduced acute pancreatitis risk versus placebo by 6.91 events per 100 person-years in participants with diabetes.
Olezarsen substantially lowered triglycerides and reduced acute pancreatitis risk in patients with severe hypertriglyceridemia and diabetes, according to an analysis of 2 phase 3 randomized trials published in Diabetes. Triglyceride reductions were similar regardless of diabetes status, while participants with diabetes experienced a higher pancreatitis rate.
The analysis evaluated olezarsen, an antisense oligonucleotide targeting APOC3, in CORE-TIMI 72a and CORE2-TIMI 72b randomized controlled trials. Investigators focused on treatment efficacy in patients with diabetes and compared their triglyceride levels and pancreatitis outcomes with those of participants without diabetes.
CORE-TIMI 72a enrolled 617 participants and CORE2-TIMI 72b enrolled 446. Eligible patients had severe hypertriglyceridemia, defined as triglycerides ≥500 mg/dL. Participants were randomized 1:1:1 to subcutaneous olezarsen 50 mg, olezarsen 80 mg, or placebo every 4 weeks for 12 months. The primary endpoint was placebo-adjusted percentage change in triglycerides at 6 months; acute pancreatitis was a secondary endpoint.
Study Findings
Of 1,063 participants, 673 (63%) had diabetes. Their median HbA1c was 7.3%, median diabetes duration was 9 years, 25% used GLP-1 receptor agonists, and 37% used insulin. Baseline triglycerides were similar in participants with and without diabetes: 784 versus 807 mg/dL (P = .43). However, prior acute pancreatitis was more common with diabetes, at 21% versus 14% (P = .005). During the trial, pancreatitis rates were 3.76 versus 1.04 events per 100 person-years, respectively (incidence rate ratio, 3.6; 95% CI, 1.1–12.0; P = .034).
Among participants with diabetes, placebo-adjusted triglyceride reductions were 57.4% (95% CI, 48.6%–66.2%) with 50 mg and 64.8% (95% CI, 56.0%–73.6%) with 80 mg. Corresponding reductions without diabetes were 57.0% and 65.1%. Pooled olezarsen treatment reduced acute pancreatitis rates versus placebo by 6.91 events per 100 person-years among participants with diabetes and 2.86 events per 100 person-years among those without diabetes.
Clinical Implications
According to the authors, olezarsen lowered triglycerides and pancreatitis risk in patients with severe hypertriglyceridemia and diabetes, a population they identified as having higher baseline pancreatitis risk.
Expert Commentary
“Olezarsen lowered TGs by 57–65% and risk of AP in pts with sHTG & DM, a population at higher baseline risk of AP,” the researchers concluded.
Reference
Kang YM, Bergmark B, Alexander VJ, et al. 1217-OR: ApoC3 inhibitor olezarsen markedly reduces triglycerides and risk of pancreatitis in severe hypertriglyceridemia patients with diabetes mellitus: insights from CORE-TIMI 72a and CORE2-TIMI 72b. Diabetes. 2026;75(suppl 1):1217-OR. doi:10.2337/db26-1217-OR
